Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $714 | $635 | $377 | $494 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $3 | $6 | $1 | $13 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $51 | $25 | $27 | $6 |
| Total Curr. Assets | $768 | $666 | $404 | $513 |
| Property Plant & Equip (Net) | $1 | $1 | $2 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $8 | $0 | $0 | $0 |
| Total NC Assets | $9 | $1 | $2 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $776 | $667 | $406 | $516 |
| Liabilities | – | – | – | – |
| Payables | $18 | $7 | $1 | $19 |
| Short-Term Debt | $0 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $51 | $41 | $41 | $25 |
| Total Curr. Liab. | $69 | $49 | $43 | $45 |
| LT Debt | $0 | $0 | $0 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $1 | $2 |
| Total Liabilities | $69 | $49 | $43 | $46 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,240 | -$826 | -$566 | -$355 |
| AOCI | $1 | $2 | $1 | $0 |
| Other Equity | $1,945 | $1,442 | $928 | $825 |
| Total Equity | $707 | $618 | $362 | $470 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $776 | $667 | $406 | $516 |
| Net Debt | -$714 | -$635 | -$375 | -$491 |